$NVTA

PolyPeptide Group AG reported mixed results during its Q4 2025 earnings call, with revenues slightly exceeding expectations while profit margins faced a squeeze due to rising production costs. The company highlighted a robust demand for its peptide-based therapeutics, forecasting growth in upcoming quarters. However, concerns regarding supply chain disruptions and increased competition in the biotechnology sector were also expressed. Management emphasized their commitment to innovation and strengthening partnerships to mitigate risks. Overall, the results reflect a cautious optimism amid challenging market conditions.